

Certnas



15008124



805 King Farm Blvd.  
Rockville, MD 20850 / USA


Nasdaq.com

William Slattery, CFA  
Vice President  
Listing Qualifications

By Electronic Mail

September 10, 2015

Mr. Jeffrey Thomas  
Chief, IT Services  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549



Dear Mr. Thomas:

By letter dated September 16, 2014, we advised you that The Nasdaq Stock Market (the "Exchange") had received a Form 8-A from rEVO Biologics, Inc. for registration of its Common Stock and the Exchange had approved the security for listing and registration upon official notice of issuance.

Since then, we have been advised that the company has determined not to proceed with the offering at this time. Accordingly, we hereby withdraw our earlier certification of approval.

Sincerely,

*William Slattery*